Tata Chemicals Q3 Review - Specialty Business May Aid Performance Ahead: ICICI Direct  
Tata Chemicals Magadi facility (image: Company website)

Tata Chemicals Q3 Review - Specialty Business May Aid Performance Ahead: ICICI Direct  

Bookmark

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Tata Chemicals Ltd. reported flat revenues to the tune of Rs 2606 crore against our estimate of Rs 2618 crore.

The basic chemical segment revenue was down 1% YoY to Rs 1987 crore while the same from speciality products was up 2% YoY to Rs 618 crore.

Higher growth from Magadi (up 30.5% YoY) along with India (up 7% YoY) and Europe (up 7% YoY) led growth in the basic chemical segment revenue. However, the same declined 14.9% YoY in the U.S. market.

Gross margins witnessed an improvement of 725 basis points QoQ to 79.6%, leading Ebitda to beat our estimates.

Click on the attachment to read the full report:

ICICI Direct Tata Chemical Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.